| Ol (lots) | Call Price | Strike Price | Put Price | Ol (lots) |
|---|---|---|---|---|
| - | - | 620 | ₹0.05 0% | 59,0000% |
| - | - | 640 | ₹0.2 0% | 37,0000% |
| 00% | ₹177.85 0% | 650 | ₹0.05 -75% | 63,0000% |
| - | - | 660 | ₹0.1 0% | 13,0000% |
| - | - | 670 | ₹0.05 0% | 11,0000% |
| - | - | 680 | ₹0.05 0% | 82,0000% |
| 1,0000% | ₹149.8 0% | 690 | ₹0.3 0% | 7,0000% |
| 22,0000% | ₹146 0% | 700 | ₹0.05 0% | 1,23,000-3.14% |
| - | - | 710 | ₹0.05 -50% | 5,0000% |
| 12,0000% | ₹106 0% | 720 | ₹0.05 -85.71% | 67,000-8.21% |
| 3,0000% | ₹103.8 0% | 730 | ₹0.05 -66.66% | 41,000-25.45% |
| 14,0000% | ₹109 -0.45% | 740 | ₹0.05 -66.66% | 48,000-2.04% |
| 43,000-2.27% | ₹104.95 15.32% | 750 | ₹0.05 -50% | 1,13,0005.60% |
| 74,0000% | ₹89.95 16.06% | 760 | ₹0.05 -83.33% | 42,000-8.69% |
| 32,0000% | ₹77 0% | 770 | ₹0.05 -50% | 36,000-5.26% |
| 38,0000% | ₹73.5 14.84% | 780 | ₹0.05 -75% | 32,000-27.27% |
| 49,000-3.92% | ₹64 11.69% | 790 | ₹0.1 -60% | 55,000-14.06% |
| 97,000-8.49% | ₹54 27.65% | 800 | ₹0.05 -83.33% | 1,86,000-7% |
| 46,000-6.12% | ₹42.2 32.91% | 810 | ₹0.05 -85.71% | 42,000-20.75% |
| 66,000-38.88% | ₹33.1 37.91% | 820 | ₹0.05 -88.88% | 85,000-26.72% |
| 97,000-24.80% | ₹23.65 73.89% | 830 | ₹0.05 -93.75% | 82,000-21.15% |
| 1,03,000-30.40% | ₹13.2 153.84% | 840 | ₹0.05 -97.91% | 88,000-16.19% |
| 78,000-65.78% | ₹4.9 117.77% | 850 | ₹3.9 -59.16% | 75,000-16.66% |
| 3,16,000-15.73% | ₹0.05 -95% | 860 | ₹6 -75.2% | 2,67,000-3.95% |
| 1,48,000-42.18% | ₹0.05 -90.9% | 870 | ₹18.4 -33.09% | 30,0000% |
| 78,000-44.68% | ₹0.05 -85.71% | 880 | ₹28.25 -10.74% | 10,000-9.09% |
| 2,05,000-60.42% | ₹0.05 -85.71% | 890 | ₹54 0% | 10,0000% |
| 1,22,000-33.69% | ₹0.05 -75% | 900 | ₹63 31.25% | 3,0000% |
| 13,0000% | ₹0.6 9.09% | 910 | - | - |
| 64,000-14.66% | ₹0.05 -50% | 920 | ₹82.95 0% | 2,0000% |
| 75,000-5.06% | ₹0.05 -50% | 940 | - | - |
| 22,0000% | ₹0.05 -66.66% | 960 | - | - |
The purchase is anticipated to enhance Syngene's position in the biologics contract development and manufacturing organization (CDMO) arena, specifically in the US market.
The company reported an operating EBITDA of ₹343.60 Crore in the quarter four of FY25. It registered a growth of 8.4% on a year-on-year basis.
This acquisition will also augment Syngene’s biologics capabilities and further strengthen its global presence.
The company's revenue from operations also grew healthily, up by 10.6% YoY to ₹943 crore, as against ₹853.5 crore in Q3 FY24.
Invest wise with Expert advice
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2025, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
